Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients with Diabetes and Chronic Kidney Disease.
J Am Coll Cardiol. 2013 Sep 25;
Authors: Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, Gan J, Jiang T, Li X, Wang W, Ding S, Jia S, Shen W, Wang D, Sun L, Qiu J, Wang X, Li Y, Deng J, Li J, Xu K, Xu B, Mehran R, Huo Y
Abstract
OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of rosuvastatin inpreventing Contrast-induced acute kidney injury (CIAKI) in patients with diabetes mellitus(DM) and chronic kidney disease(CKD).
BACKGROUND: CIAKI is an important complication after contrast media injection. While smallstudies have shown positive results with statin therapy, the role of statin therapy in preventionof CIAKI remains unknown.
METHODS: We randomized 2,998 patients with type 2 DM and concomitant CKD who wereundergoing coronary/peripheral arterial angiography with or without percutaneousintervention to rosuvastatin 10 mg/day (n=1,498) for five days (two days before, three dayspost procedure) or standard-of-care (n=1,500). Renal function was assessed at baseline, 48, and 72 hours after contrast media exposure. The primary endpoint of the study was thedevelopment of CIAKI, which was defined as an increase in serum creatinine concentration.0.5 mg/dL (44.2ƒÊmol/L) or .25% above baseline at 72 hours after exposure to contrast media.
RESULTS: Patients randomized to the rosuvastatin group had a significantly lower incidence ofCIAKI compared to controls (2.3% vs 3.9%;P=0.01; OR=0.58, 95%CI 0.38, 0.89).During 30 days follow-up, rate of worsening heart failure was significantly lower in patients treated with rosuvastatin than that in control group(2.6% vs 4.3%;P=0.02).Conclusion. Rosuvastatin significantly reduced the risk of CIAKI in patients with DM andCKD undergoing arterial contrast media injection.
PMID: 24076297 [PubMed - as supplied by publisher]